Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 2,000
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 f...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 8 6151 0992
Website: pyctx.com
Address:
Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, Australia
Latest News on PYCXF
No data available.